Avidity Biosciences Inc. - Form 8-K Filing

Avidity Biosciences Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on February 18, 2026. This filing serves as a notice regarding the delisting of its common stock from The Nasdaq Capital Market. The company is providing this information as required by SEC regulations for material events affecting listed securities.

This delisting notice does not appear to impose new compliance obligations on the company beyond the standard reporting requirements. Investors and stakeholders should note that the company's common stock will continue to be traded on The Nasdaq Global Select Market, indicating no disruption to its primary listing. No specific actions are required from compliance officers beyond acknowledging the filing and its implications for the company's listing status.